A comparative review of conventional and lipid formulations of amphotericin B

Journal of Clinical Pharmacy and Therapeutics

Volumn 24, Issue 4, 1999, Pages 249-257

  Robinson, R F ^a   Nahata, M C ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT;

ANEMIA; ANOREXIA; ANTIBIOTIC THERAPY; ANTIFUNGAL ACTIVITY; APNEA; ARTHRALGIA; BRONCHOSPASM; CHILL; CLINICAL TRIAL; CORTICOSTEROID THERAPY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; FATIGUE; FEVER; HEADACHE; HEART ARRHYTHMIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOTENSION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY TUBULE ACIDOSIS; MAJOR CLINICAL STUDY; META ANALYSIS; MYALGIA; MYCOSIS; NEPHROTOXICITY; PRACTICE GUIDELINE; REVIEW; SHOCK; STOMACH PAIN; STRIDOR; WEIGHT REDUCTION;

AMPHOTERICIN B; ANTIBIOTICS, ANTIFUNGAL; CHEMISTRY, PHARMACEUTICAL; HUMANS; LIPIDS; LIPOSOMES; MYCOSES;

EID: 0032811616     PISSN: 02694727     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2710.1999.00220.x     Document Type: Review

References (33)

1. 1. Banerjee SN, Emori TG, Culver DH et al. (1991) Secular trend in nosocomial primary bloodstream infections in the US, 1980-1989. American Journal of Medicine, 91 (supplement 3B), 86S-9S.
2. 2. Rinaldi MG. (1983) Invasive aspergillosis. Review of Infectious Diseases, 5, 1061.
3. 3. Hoeprich P. (1992) Clinical use of amphotericin B and derivatives: lore, mystique, and fact. Clinical Infectious Diseases, 14, S114-S119.
4. 4. Clements JS Jr., Peacock JE Jr. (1990) Amphotericin B revisited: reassessment of toxicity. American Journal of Medicine, 88, 5-22n-27n.
5. 5. Anaissie E. (1992) Opportunistic mycoses in the immunocompromised host: experience at a cancer center and review. Clinical Infectious Diseases, 14, S43-53.
6. 6. Graybill JR. (1988) Systemic fungal infections: diagnosis and treatment. I. Therapeutic agents. Infectious Disease Clinics of North America, 2, 805.
7. 7. Kintzel PE, Smith GH. (1992) Practical guidelines for the preparing and administering amphotericin B. American Journal of Hospital Pharmacy, 49, 1156-1164.
8. 8. Carlson MA, Condon RE. (1994) Nephrotoxicity of amphotericin B. Journal of American College Surgeons, 179, 361-381.
9. 9. Kennedy MS, Deeg HJ, Siegel M. (1983) Acute renal toxicity with combined use of amphotericin B and cyclosporine after marrow transplantation. Transplantation, 35, 211-215.
10. 10. Wong-Beringer A, Jacobs RA, Guglielmo BJ. (1998) Lipid formulations of amphotericin B: clinical efficacy and toxicities. Clinical Infectious Diseases, 27, 603-618.
11. 11. Merhav H, Mieles L. (1997) Amphotericin B lipid complex in the treatment of invasive fungal infections in the liver transplant patients. Transplant Proceedings, 29, 2670-2674.
12. 12. Madden TD, Janoff AS, Cullis PR. (1990) Incorporation of amphotericin B into large unilamellar vesicles composed of phosphatidylcholine and phosphatidylglycerol. Chemical Phys Lipids, 52, 189-198.
13. 13. Wingard JR. (1997) Efficacy of amphotericin B lipid complex injection (ABLC) in bone marrow recipients with life-threatening systemic nycoses. Bone Marrow Transplant, 19, 343-347.
14. 14. Sharkey PK, Graybill JR, Johnson ES et al. (1996) Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS. Clinical Infectious Diseases, 22, 315-321.
15. 15. Powderly WG. (1996) Editorial response: management of cryptococcal meningitis - have we answered all the questions? Clinical Infectious Diseases, 22, 329-330.
16. 16. Hiemenz JW, Lister J, Anaissie E et al. (1995) Emergency-use amphotericin B lipid complex (ABLC) in the treatment of aspergillosis; historical control comparison with amphotericin B. (Abstract no. 3383). Blood, 86, 849a.
17. 17. Jones RS, Barman A, Suh B et al. (1995) Successful treatment of aspergillus vertebral osteomyelitis with amphotericin B lipid complex. Infectious Disease and Clinical Practice, 4, 237-239.
18. 18. Lister J. (1996) Amphotericin B lipid complex (Abelcet) in the treatment of invasive mycoses: the North American experience. European Journal of Haematology, 56, 18-23.
19. 19. White MH, Bowden RA, Sandler E et al. (1996) Amphotericin B colloidal dispersion (ABCD) versus amphotericin B (AmB) in the empiric treatment of febrile neutropenic patients. Blood, 88, 320a.
20. 20. Anon (1997) Amphotericin B Colloidal Dispersion (Amphotec) product information. Sequus Pharmaceuticals. Merlo, CA.
21. 21. Trissel LA. (1998) Handbook on Injectable Drugs. 10th edition. Bethesda, Maryland: American Society of Health-System Pharmacists.
22. 22. Allende MC, Lee JW, Francis P et al. (1994) Dose-dependent antifungal activity and nephrotoxicity of amphotericin B colloidal dispersion in experimental pulmonary aspergillosis. Antimicrobiol Agents Chemotherapy, 38, 518-522.
23. 23. White MH, Anaissie EJ, Kusne S et al. (1997) Amphotoricin B colloidal dispersion versus amphotericin B as therapy for invasive aspergillosis. Clinical Infectious Diseases, 24, 635-642.
24. 24. Bowden RA, Cays M, Gooley T et al. (1996) Phase I study of amphotericin B colloidal dispersion for the treatment of invasive fungal infections after bone marrow transplant. Journal of Infectious Disease, 172, 1208-1215.
25. 25. Oppenheim BA, Herbrecht R, Kusne S. (1993) The safety and efficacy of amphotericin B colloidal dispersion in the treatment of invasive mycosis. Clinical Infectious Diseases, 17, 981-986.
26. 26. Ringden O, Meunier F, Tollemar J et al. (1991) Efficacy of amphotericin B encapsulated in liposomes (Am-Bisome) in the treatment of invasive fungal infections in immunocompromised patients. Journal of Antimicrobial Chemotherapy, 28, 73-82.
27. 27. Persson U, Regnarsson Tennuall G, Andersson S et al. (1992) Cost effectiveness analysis of treatment with liposomal amphotericin B versus conventional amphotericin B in organ or bone marrow transplant recipients with systemic mycoses. PharmacoEconomics, 2, 500-508.
28. 28. Prentice HG, Hann IM, Herbrecht R et al. (1997) A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients, British Journal of Haematology, 998, 711-718.
29. 29. Coker RJ, Viviani M, Gazzard BG et al. (1993) Treatment of cryptococcosis with liposomal amphotericin B (Am-Bisome) in 23 patients with AIDS. AIDS, 7, 829-835.
30. 30. Merhav H, Mieles L. (1997) Amphotericin B lipid complex in the treatment of invasive fungal infections in liver transplant patients. Transplant Proceedings, 29, 2670-2674.
31. 31. Gubbins PO. (1998) Defining the role of lipid-based amphotericin B formulations. SIDP Newsletter, May 1998.
32. 32. Pathak A, Pien FD, Carvalho L. (1998) Amphotericin B use in the community hospital, with special emphasis on side effects. Clinical Infectious Diseases, 26, 334-338.
33. 33. Patterson TF. (1998) Editorial response: approaches to therapy for invasive mycoses - the role of amphotericin B. Clinical Infectious Diseases, 26, 339-340.